
CLAIMS

What is claimed is:

1. A composition comprising at least one compound of Formula I:



Formula I

its stereoisomers or pharmaceutically acceptable salts thereof;

wherein

R^1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R^1 is aryl, heteroaryl or heterocycloalkyl, R^1 is unsubstitued or substitued with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO_2NHR^2, or COR^3;

R^2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;

R^3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;

R^4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO_2R^5, or COR^3;

R^5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;


R^6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl;

X is selected from O, $(CH_2)p$, NH and p is from 0-2; and

Y_1-Y_2 are selected from CH-CH_2 or C=CH; and

Y3 is selected from H or Me

2. A composition according to claim 1, according to Formula II:



Formula II

its stereoisomers or pharmaceutically acceptable salts thereof;

wherein

R^1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R^1 is aryl, heteroaryl or heterocycloalkyl, R^1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO_2NHR^2, or COR^3;

R^2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;

R^3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;

R^4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO_2R^5, COR^3;


R^5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;

R^6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl;

X is selected from O, $(CH_2)p$, NH and p is from 0-2; and

Y_1-Y_2 are selected from CH-CH_2 or C=CH.

3. A composition according to claim 1, according to Formula III



Formula III

its stereoisomers or pharmaceutically acceptable salts thereof;

wherein

R^1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R^1 is aryl, heteroaryl or heterocycloalkyl, R^1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO_2R^5, SO_2NHR^2, or COR^3;

R^2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;

R^3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;


R^4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO_2R^5, SO_2NHR^2, COR^3;

R^5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;

R^6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl; and

X is selected from O, $(CH_2)p$, NH and p is from 0-2.

4. A composition according to claim 1, wherein composition is according to Formula IV



Formula IV

its stereoisomers or pharmaceutically acceptable salts thereof;

wherein

R^1 is selected from a group consisting of alkyl, hydrogen, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl and wherein when R^1 is aryl, heteroaryl or heterocycloalkyl, R^1 is unsubstituted or substituted with alkyl, hydroxy, halogen, haloalkyl, hydroxyalkyl, alkoxyalkyl, alkoxy, amine, SO_2R^5, SO_2NHR^2, COR^3;

R^2 is selected from a group consisting of hydrogen, alkyl, haloalkyl, or cycloalkyl;

R^3 is selected from a group consisting of alkyl, cycloalkyl, hydroxy, amine, alkyamine or alkoxy;


R^4 is selected from a group consisting of hydrogen, alkyl, halogen, haloalkyl, hydroxy, amine, alkoxy, SO_2R^5, COR^3;


R^5 is selected from a group consisting of alkyl, haloalkyl, cycloalkyl, aryl or amine;


R^6 is selected from a group consisting of alkyl, cycloalkyl, aryl or heteroaryl. Aryl or heteroaryl may optionally be substituted one or more times with groups or substituents such as alkyl, hydroxy, halogen, haloalkyl; and


X is selected from O, $(CH_2)p$, NH; wherein p is selected from 0-2.


5. A composition according to claim 1, comprising one or more of the following compounds, its stereoisomers or pharmaceutically acceptable salts thereof:







































6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least one compound of any one of claims 1 to 5.

7. Use of a composition of any one of claims 1 to 6 in the manufacture of a medicament for treatment of pain, neurodegenerative disease, or inflammatory disease in a subject.


8. The use according to claim 7, wherein the medicament further comprises a compound according to Formula II



Formula II,

its stereoisomers or pharmaceutically acceptable salts thereof.


9. The use according to claim 7, wherein the medicament further comprises a compound according to Formula III



Formula III,

its stereoisomers or pharmaceutically acceptable salts thereof.


10. The use according to claim 7, wherein the medicament further comprises a compound according to Formula IV





Formula IV,


its stereoisomers or pharmaceutically acceptable salts thereof.


11. The use according to claim 7, wherein the medicament further comprises a compound selected from one or more of:






































.

12. Use of the composition of claim 1 or claim 2 in the manufacture of a medicament for treatment of neuropathic or inflammatory pain in a subject.

13. Use of the composition of claim 1 or claim 2 in the manufacture of a medicament for treatment of Parkinson's disease in a subject.

14. Use of the composition of claim 1 or claim 2 in the manufacture of a medicament for treatment of diabetic peripheral neuropathy in a subject.

15. The use of claim 12, wherein the neuropathic pain is peripheral neuropathic pain.

16. The use of claim 12, wherein the neuropathic pain is selected from a group consisting of post-herpetic neuralgia, trigeminal neuralgia, focal peripheral nerve injury, anesthesia dolorosa central pain, spinal cord injury, multiple sclerosis, peripheral neuropathy, HIV, or chemotherapy-induced pain.